1Berman SM, Chang L, Suyenobu B, et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron[J]. Gastroenterology, 2002,123 (4) : 969-977. 被引量：1
2Chey WD,Cash BD. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea[J]. Expert Opin nvestig Drugs, 2005,14(2) :185-193. 被引量：1
3Hirata T, Keto Y, Funatsu T, et al. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome[J]. J Pharmaeol Sci, 2007, 104(3) : 263-273. 被引量：1
4Bharucha AE, Camilleri M, Haydock S, et al. Effects of a serotonin 5-HT ( 4 ) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans[J].Gut ,2000,47(5) : 667-674. 被引量：1
5Coremans G, Kerstens R, de Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a doubleblind, placebo-controlled clinical trial[J]. Digestion, 2003,67(1/2):82-89. 被引量：1
6Tack J, Middleton SJ, Horne MC, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2006,23 (11) : 1655-1665. 被引量：1
7Wei W, Ge ZZ, Lu H, et al. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy[J]. J Gastroenterol Hepatol, 2007, 22 (10) : 1605- 1608. 被引量：1
8Foxx-Orenstein AE, Camilleri M, Szarka LA, et at. Does co- administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation- predominant irritable bowel syndrome? A randomized controlled trial [ J ]. Neurogastroenterol Motil, 2007, 19 ( 10 ) : 821-830. 被引量：1
9Viramontes BE, Malcolm A, Camilleri M, et al. Effects of an alpha(2)-adrenergie agonist on gastrointestinal transit, colonic motility, and sensation in humans [J]. Am J Physiol Gastrointest Liver Physiol,2001,281(6) :G1468-1476. 被引量：1
10Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of elonidine in diarrhea- predominant irritable bowel syndrome[J]. Clin Gastroenterol Hepatol,2003,1(2) :111-121. 被引量：1
5Mann NS,Limoges-Gonzales M.The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome[J].Hepatogastroenterology,2009,56 (91-92):718-721. 被引量：1
6Kaur J,Rana SV,Gupta R,et al.Prolonged orocecal transit time enhances serum bile acids through bacterial overgrowth,contributing factor to gallstone disease[J].J Clin Gastroenterol,2014,48(4):365-369. 被引量：1
7Nucera G,Gabrielli M,Lupascu A,et al.Abnormal breath tests to lactose,fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth[J].Aliment Pharmacol Ther,2005,21(11):1391-1395. 被引量：1
8Sinn DH,Song JH,Kim HJ,et al.Therapeutic effect of Lactobacillus acidophilus-SDC 2012,2013 in patients with irritable bowel syndrome[J].Dig Dis Sci,2008,53 (10):2714-2718. 被引量：1
9Cuoco L,Montalto M,Jorizzo RA.et al.Eradication of small intestinal bacterial overgrowth and orocecal transit in diabetics[J].Hepatogastroenterology,2002,49(48):1582-1586. 被引量：1
10Douglas A. Drossman.The Functional Gastrointestinal Disorders and the Rome III Process[J].Gastroenterology.2006(5) 被引量：24
